Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$238.75 USD

238.75
1,334,422

-5.37 (-2.20%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View

IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.

CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates

CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.

Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates

Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss

PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2

Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

Masimo (MASI) raises its 2019 product revenue guidance.

Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss

Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.

McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat

McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.

Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates

Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.

Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat

Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

Here's Why You Should Add ResMed (RMD) to Your Portfolio

Investors continue to be optimistic about ResMed's (RMD) performance.

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3

Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.

Company News For Oct 28, 2019

Companies in the news are: AMZN, BOOM, RMD, MLNT

Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall

Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.

ResMed (RMD) Hits 52-Week High, Can the Run Continue?

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View

Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.

ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand

ResMed (RMD) registers growth at CER across its key operating segments in Q1.

Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y

Cerner (CERN) Q3 results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

NextGen (NXGN) Q2 Earnings Beat, Revenues Miss Estimates

NextGen (NXGN) retains its fiscal 2020 revenue and EPS guidance.

GNC Holdings (GNC) Q3 Loss Meets Estimates, Revenues Miss

GNC Holdings' (GNC) third-quarter 2019 results, reflecting dismal performance across segments, disappoint investors.

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.

3 Reasons Growth Investors Will Love ResMed (RMD)

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.